文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported.

作者信息

Bins Sander, Sardh Eliane, Langendonk Janneke G

机构信息

Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Karolinska University Hospital, Stockholm, Sweden.

出版信息

Clin Pharmacol Ther. 2022 Jul;112(1):24. doi: 10.1002/cpt.2597. Epub 2022 Apr 21.

DOI:10.1002/cpt.2597
PMID:35446989
Abstract
摘要

相似文献

[1]
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported.

Clin Pharmacol Ther. 2022-7

[2]
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved -Acetylgalactosamine-Conjugated RNA Interference Therapeutic.

Drug Metab Dispos. 2021-7

[3]
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.

Clin Pharmacol Ther. 2021-11

[4]
Givosiran: First Approval.

Drugs. 2020-2

[5]
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.

N Engl J Med. 2020-6-11

[6]
Acute intermittent porphyria, givosiran, and homocysteine.

J Inherit Metab Dis. 2021-7

[7]
Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Mol Diagn Ther. 2020-2

[8]
[Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].

Z Gastroenterol. 2020-8

[9]
Homocysteine elevation in givosiran treatment: Suggested ALAS1 siRNA effect on cystathionine beta-synthase.

J Intern Med. 2021-10

[10]
Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran.

J Neurol Sci. 2021-3-15

引用本文的文献

[1]
Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.

Drug Metab Dispos. 2023-2

[2]
Iron Metabolism in the Disorders of Heme Biosynthesis.

Metabolites. 2022-8-31

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索